Acyclic Retinoid Induces Apoptosis in Liver Cancer Cells
Author Information
Author(s): Tatsukawa Hideki, Sano Tetsuro, Fukaya Yayoi, Ishibashi Naoto, Watanabe Makiko, Okuno Masataka, Moriwaki Hisataka, Kojima Soichi
Primary Institution: RIKEN Advanced Science Institute
Hypothesis
Can acyclic retinoid restore the expression of TG2 and downregulate growth factor receptors to induce apoptosis in hepatocellular carcinoma cells?
Conclusion
Acyclic retinoid treatment activates both caspase 3 and TG2, leading to apoptosis in hepatocellular carcinoma cells by modifying and inactivating Sp1, which reduces the expression of the epidermal growth factor receptor.
Supporting Evidence
- Acyclic retinoid treatment induced apoptosis in hepatocellular carcinoma cells but not in normal hepatocyte cells.
- ACR treatment reduced the expression of epidermal growth factor receptor in JHH-7 cells.
- Both caspase 3 and TG2 pathways were activated in ACR-treated cells, leading to apoptosis.
- ACR suppressed the hyper-phosphorylation of RXRα, restoring its transcriptional function.
- ACR treatment resulted in increased levels of crosslinked Sp1 in apoptotic cells.
Takeaway
Acyclic retinoid helps kill liver cancer cells by turning on special proteins that make the cells die, while also stopping them from growing.
Methodology
The study used human hepatocellular carcinoma cells in culture, nude mice transplanted with these cells, and rats treated with N-diethylnitrosamine to assess the effects of acyclic retinoid on apoptosis.
Potential Biases
Potential bias due to the use of animal models which may not fully replicate human responses.
Limitations
The study does not explore the long-term effects of acyclic retinoid treatment or its efficacy in human patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website